AbbVie Completes Acquisition of Cerevel Therapeutics
AbbVie (NYSE: ABBV) has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE), strengthening its neuroscience portfolio. The acquisition brings multiple clinical-stage assets, including emraclidine, a potential best-in-class antipsychotic for schizophrenia, and tavapadon, a first-in-class treatment for Parkinson's disease. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2030.
The company reaffirms its 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91, which includes a $0.19 per share dilutive impact from the Cerevel acquisition. AbbVie also maintains its third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. The acquisition is expected to contribute to AbbVie's long-term performance and complement its existing neuroscience pipeline.
AbbVie (NYSE: ABBV) ha completato l'acquisizione di Cerevel Therapeutics (NASDAQ: CERE), rafforzando il proprio portafoglio nel settore neuroscientifico. L'acquisizione porta con s茅 diversi asset in fase clinica, tra cui emraclidine, un potenziale antipsicotico di eccellenza per la schizofrenia, e tavapadon, un trattamento innovativo per il morbo di Parkinson. AbbVie prevede che l'acquisizione contribuir脿 in modo positivo all'EPS diluito rettificato a partire dal 2030.
L'azienda conferma la sua previsione per l'EPS diluito rettificato per l'intero anno 2024, che si attesta tra $10.71 e $10.91, includendo un impatto diluitivo di $0.19 per azione derivante dall'acquisizione di Cerevel. AbbVie mantiene anche la propria stima per l'EPS diluito rettificato del terzo trimestre, compresa tra $2.92 e $2.96. Si prevede che l'acquisizione contribuir脿 alla performance a lungo termine di AbbVie e completer脿 il suo attuale pipeline neuroscientifico.
AbbVie (NYSE: ABBV) ha completado la adquisici贸n de Cerevel Therapeutics (NASDAQ: CERE), fortaleciendo su portafolio en neurociencia. La adquisici贸n incluye m煤ltiples activos en etapa cl铆nica, entre ellos emraclidine, un antipsic贸tico potencialmente de primera clase para la esquizofrenia, y tavapadon, un tratamiento in茅dito para la enfermedad de Parkinson. AbbVie espera que la adquisici贸n sea positiva para el EPS diluido ajustado a partir de 2030.
La compa帽铆a reafirma su rango de orientaci贸n del EPS diluido ajustado para todo el a帽o 2024 de $10.71 a $10.91, que incluye un impacto dilutivo de $0.19 por acci贸n derivado de la adquisici贸n de Cerevel. AbbVie tambi茅n mantiene su rango de orientaci贸n del EPS diluido ajustado para el tercer trimestre de $2.92 a $2.96. Se espera que la adquisici贸n contribuya al desempe帽o a largo plazo de AbbVie y complemente su actual pipeline de neurociencia.
AbbVie (NYSE: ABBV)電� Cerevel Therapeutics (NASDAQ: CERE)鞚� 鞚胳垬毳� 鞕勲頃橃棳 鞁犼步瓿柬暀 韽姼韽措Μ鞓るゼ 臧曧檾頄堨姷雼堧嫟. 鞚措矆 鞚胳垬電� 鞐煬 鞛勳儊 雼硠 鞛愳偘鞚� 韽暔頃橂┌, 韸鬼瀳 emraclidine鞚� 臁绊槃氤戩棎 雽�頃� 斓滉碃鞚� 韥措灅鞀る 鞐波歆�電� 鞛犾灛鞝� 頃爼鞁犽硲鞝滌澊瓿�, tavapadon鞚� 韺岉偍鞀硲鞚� 鞙勴暅 斓滌磮鞚� 旃橂鞝滌瀰雼堧嫟. AbbVie電� 鞚胳垬臧� 2030雲勲秬韯� 臁办爼霅� 頋劃 EPS鞐� 旮嶌爼鞝侅澑 鞓來枼鞚� 氙胳範 瓴冹溂搿� 旮半寑頃橁碃 鞛堨姷雼堧嫟.
鞚� 須岇偓電� 2024雲� 鞝勳泊 鞐半弰 臁办爼 頋劃 EPS 臧�鞚措崢鞀� 氩旍渼毳� $10.71-$10.91搿� reaffirm頃橂┌, 鞚措姅 Cerevel 鞚胳垬搿� 鞚疙暅 欤茧嫻 $0.19鞚� 頋劃 須臣毳� 韽暔頃╇媹雼�. AbbVie電� 霕愴暅 3攵勱赴 臁办爼 頋劃 EPS 臧�鞚措崢鞀� 氩旍渼毳� $2.92-$2.96鞙茧 鞙犾頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 鞚胳垬電� AbbVie鞚� 鞛リ赴 靹标臣鞐� 旮办棳頃橁碃 旮办〈 鞁犼步瓿柬暀 韺岇澊頂勲澕鞚胳潉 氤挫檮頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
AbbVie (NYSE: ABBV) a finalis茅 son acquisition de Cerevel Therapeutics (NASDAQ: CERE), renfor莽ant ainsi son portefeuille en neurosciences. Cette acquisition apporte plusieurs actifs en phase clinique, y compris emraclidine, un antipsychotique potentiel de premier ordre pour la schizophr茅nie, et tavapadon, un traitement de premi猫re classe pour la maladie de Parkinson. AbbVie s'attend 脿 ce que l'acquisition ait un impact positif sur l'EPS dilu茅 ajust茅 脿 partir de 2030.
L'entreprise r茅affirme son intervalle de pr茅vision de l'EPS dilu茅 ajust茅 pour l'ann茅e compl猫te 2024, qui s'茅l猫ve 脿 $10.71-$10.91, incluant un impact dilutif de $0.19 par action provenant de l'acquisition de Cerevel. AbbVie maintient 茅galement son intervalle de pr茅vision de l'EPS dilu茅 ajust茅 pour le troisi猫me trimestre, qui est de $2.92-$2.96. L'acquisition devrait contribuer 脿 la performance 脿 long terme d'AbbVie et compl茅ter son pipeline de neurosciences existant.
AbbVie (NYSE: ABBV) hat die 脺bernahme von Cerevel Therapeutics (NASDAQ: CERE) abgeschlossen und st盲rkt damit sein Neurowissenschafts-Portfolio. Die 脺bernahme bringt mehrere klinische Entwicklungsprojekte mit sich, einschlie脽lich emraclidine, einem potenziellen erstklassigen Antipsychotikum f眉r Schizophrenie, und tavapadon, einer neuartigen Behandlung f眉r die Parkinson-Krankheit. AbbVie geht davon aus, dass die 脺bernahme ab 2030 positiv zur adjusted diluted EPS beitragen wird.
Das Unternehmen bekr盲ftigt seine Prognose f眉r das gesamte Jahr 2024 f眉r adjusted diluted EPS im Bereich von $10.71 bis $10.91, was eine verw盲ssernde Auswirkung von $0.19 pro Aktie aus der Cerevel-脺bernahme beinhaltet. AbbVie h盲lt auch die Guidance f眉r adjusted diluted EPS im dritten Quartal im Bereich von $2.92 bis $2.96 aufrecht. Die 脺bernahme wird voraussichtlich zur langfristigen Leistung von AbbVie beitragen und die bestehende Neurowissenschafts-Pipeline erg盲nzen.
- Acquisition of Cerevel Therapeutics strengthens AbbVie's neuroscience portfolio
- Emraclidine, a potential best-in-class antipsychotic for schizophrenia, is in registration-enabling trials
- Tavapadon, a first-in-class treatment for Parkinson's disease, met primary endpoint in a Phase 3 study
- Acquisition expected to be accretive to adjusted diluted EPS beginning in 2030
- Reaffirmation of 2024 full-year and third-quarter adjusted diluted EPS guidance
- $0.19 per share dilutive impact on 2024 EPS due to Cerevel acquisition
- $0.60 per share unfavorable impact on 2024 EPS from acquired IPR&D and milestones expense
Insights
The acquisition of Cerevel Therapeutics by AbbVie is a significant strategic move that strengthens AbbVie's position in the neuroscience market. This deal, valued at
Key financial points to consider:
- AbbVie has reaffirmed its 2024 full-year adjusted diluted EPS guidance range of
$10.71 -$10.91 , including a$0.19 per share dilutive impact from the Cerevel acquisition. - The company's Q3 2024 adjusted diluted EPS guidance remains at
$2.92 -$2.96 . - The guidance includes an unfavorable impact of
$0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q2 2024.
While the acquisition will be dilutive in the short term, the long-term potential for revenue growth into the next decade is promising. Investors should monitor the progress of Cerevel's pipeline assets, particularly emraclidine and tavapadon, as their success could significantly impact AbbVie's future revenue streams.
AbbVie's acquisition of Cerevel Therapeutics marks a strategic expansion in the neuroscience sector, particularly in areas with high unmet needs. The deal brings several promising candidates to AbbVie's pipeline:
- Emraclidine: A potential best-in-class antipsychotic for schizophrenia, affecting approximately 24 million people worldwide. Its novel mechanism as a muscarinic M4 receptor PAM could offer improved efficacy and tolerability.
- Tavapadon: A first-in-class dopamine D1/D5 selective partial agonist for Parkinson's disease, currently in Phase 3. Its potential use in early-stage Parkinson's could complement AbbVie's existing therapies for advanced stages.
- CVL-354: A Phase 1 kappa opioid receptor antagonist for major depressive disorder, potentially offering better efficacy and tolerability than current treatments.
- Darigabat: A Phase 2 GABAA receptor PAM for treatment-resistant epilepsy and panic disorder.
This diverse pipeline addresses significant markets in neurology and psychiatry. The success of these candidates, particularly emraclidine and tavapadon, could substantially boost AbbVie's neuroscience portfolio and market position in the coming years.
The AbbVie-Cerevel merger represents a strategic consolidation in the competitive neuroscience market. This acquisition addresses several key market dynamics:
- Market Expansion: AbbVie gains access to potential treatments for schizophrenia, early-stage Parkinson's disease and major depressive disorder, expanding its addressable market.
- Pipeline Diversification: The addition of Cerevel's assets complements AbbVie's existing portfolio, potentially reducing reliance on current blockbuster drugs.
- Innovation in Unmet Needs: Cerevel's novel mechanisms of action, particularly in schizophrenia and depression, target areas where current treatments often fall short.
- Long-term Growth Strategy: The expected EPS accretion by 2030 suggests AbbVie is positioning itself for sustained growth in the next decade.
However, investors should note the inherent risks in drug development, particularly in neuroscience where failure rates are historically high. The success of this acquisition will largely depend on the clinical outcomes of key assets like emraclidine and tavapadon. If successful, AbbVie could significantly strengthen its competitive position against other major players in the neuroscience market.
- Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease
- Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
- Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade
- AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPSrticles/eps-explained-simple-example" title="Read: EPS Explained with a Simple Example: The Most Important Stock Metric" class="article-link" rel="noopener">diluted EPS guidance range of
$10.71 -$10.91 $2.92 -$2.96
"AbbVie's听acquisition听of听Cerevel strengthens听our听foundation听in听neuroscience听and听positions听us听to deliver sustainable long-term performance into the next decade and beyond," said Robert A. Michael, chief executive officer, AbbVie. "Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie."
There are multiple programs in Cerevel's pipeline across several neurological and psychiatric conditions such as schizophrenia, Parkinson's disease and mood disorders, where there continues to be significant unmet need for patients. Cerevel's pipeline is highly complementary to听AbbVie's existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new and better tolerated therapies.
Emraclidine,听a听potential听best-in-class,听next-generation听antipsychotic,听is听a听positive allosteric modulator (PAM) of the muscarinic M4 receptor that is being studied for the treatment of schizophrenia 鈥� a disease that affects听approximately 24听million people worldwide.1 In a听Phase 1b听study,听emraclidine has shown promising efficacy and safety and is currently completing two Phase 2 trials that were designed to be registration enabling.
Tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson's disease,听is currently in Phase听3 studies and has听potential听for听both听monotherapy听and adjunctive听treatment.听Tavapadon's听efficacy and听safety-tolerability听profile could听enable听its听utility听in early Parkinson's disease, becoming a near-term complementary asset to AbbVie's existing symptomatic therapies for advanced Parkinson's disease. Recently, tavapadon met the primary endpoint in a pivotal Phase 3 study and data from additional Phase 3 trials of tavapadon are expected later this year.
CVL-354, currently in Phase 1, is a potential best-in-class kappa opioid receptor (KOR) antagonist that has the potential to provide significantly improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD). Darigabat, currently in Phase听2,听is听an听alpha听2/3/5听selective GABAA receptor PAM for treatment-resistant epilepsy and panic disorder.
贵辞谤听补诲诲颈迟颈辞苍补濒听产补肠办驳谤辞耻苍诲听辞苍听迟丑别听补肠辩耻颈蝉颈迟颈辞苍,听辫濒别补蝉别听谤别补诲听迟丑别听补苍苍辞耻苍肠别尘别苍迟听辫谤别蝉蝉听谤别濒别补蝉别 听and view AbbVie's investor presentation .
贵颈苍补苍肠颈补濒听罢别谤尘蝉
AbbVie听has听acquired听all听outstanding听Cerevel common听stock听for
贵耻濒濒-驰别补谤听2024听翱耻迟濒辞辞办
AbbVie听is听reaffirming听its听previously听issued 2024听full-year听adjusted diluted听EPS听guidance range of
AbbVie听is听reaffirming听its听previously听issued 2024听third-quarter听adjusted diluted听EPS听guidance range of
__________________ 1听World听Health Organization:听Schizophrenia听Key听Facts.听Available听at: 听听January 10, 2022. |
About听AbbVie听in听Neuroscience
At AbbVie, our commitment to preserving personhood of people around the world living with neurological and psychiatric disorders is unwavering. With more than three decades of experience in neuroscience, we are providing meaningful treatment options today and advancing innovation for the future. AbbVie's Neuroscience portfolio consists of approved treatments in neurological conditions, including migraine, movement disorders and psychiatric disorders, along with a robust pipeline of transformative therapies. We have made a strong investment in research and are committed to building a deeper understanding of neurological and psychiatric disorders. Every challenge makes us more determined and drives us to discover and deliver advancements for those impacted by these conditions, their care partners and clinicians. For more information, visit听
About听AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas 鈥� immunology, oncology, neuroscience and eye care 鈥� and products and services in our听Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on , , 听and
Forward-Looking Statements
Some statements in this news release, including those relating to the acquisition of Cerevel by AbbVie, are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward- looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period, the risk that the businesses will not be integrated successfully, disruption from the transaction making it more difficult to maintain business and operational relationships, negative effects of the consummation of the acquisition on the market price of听AbbVie's common stock and/or operating results, significant transaction costs, unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition or Cerevel's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect听AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q.听AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content:
SOURCE AbbVie
FAQ
What is the impact of Cerevel acquisition on AbbVie's (ABBV) 2024 earnings?
When will the Cerevel acquisition be accretive to AbbVie's (ABBV) earnings?
What are the key assets AbbVie (ABBV) gained from the Cerevel acquisition?
How much did AbbVie (ABBV) pay per share for Cerevel Therapeutics?
